What is BTi?
BTi operates at the intersection of biotechnology and clinical healthcare, specializing in the ethical procurement and processing of amnion and birth tissue. By establishing robust partnerships with hospitals and medical providers, the firm facilitates the integration of these biological resources into advanced surgical, wound care, and dental treatment protocols. The company serves as a critical link in the medical supply chain, transforming post-birth biological materials into high-value therapeutic assets that enhance patient recovery outcomes. Their market position is defined by a commitment to donor education and the rigorous standardization of tissue-based medical solutions.
How much funding has BTi raised?
BTi has raised a total of $131K across 1 funding round:
Debt
$131K
Debt (2021): $131K with participation from PPP
Key Investors in BTi
PPP
Public-Private Partnership
What's next for BTi?
Following this late-stage investment, BTi is positioned to accelerate its operational footprint and expand its clinical reach. The strategic deployment of this capital will likely focus on enhancing processing capabilities, deepening hospital network integration, and investing in the clinical validation of new tissue-based therapies. As the demand for regenerative medicine continues to rise, BTi is well-equipped to leverage its current financial stability to capture a larger share of the medical biotechnology market, ensuring that its life-improving resources are accessible to a broader spectrum of healthcare providers and patients globally.
See full BTi company page
